H.B. No. 3057 introduces a new subchapter, Subchapter E-2, to Chapter 1369 of the Texas Insurance Code, which mandates health benefit plans to provide coverage for chimeric antigen receptor T-cell therapy. This coverage is applicable to various types of health benefit plans, including individual and group insurance policies, hospital service contracts, and health maintenance organizations. The bill specifies that the therapy must be deemed medically necessary and administered by a qualified healthcare provider that is certified and part of the health benefit plan's network.

The bill also outlines exceptions to its applicability, stating that it does not apply to issuers or providers under the state Medicaid program or the child health plan program. Additionally, the coverage requirements stipulate that the therapy must be provided by certified facilities in accordance with FDA-approved procedures. The act is set to take effect on September 1, 2025, and will apply to health benefit plans delivered, issued for delivery, or renewed on or after January 1, 2026.

Statutes affected:
Introduced: ()
House Committee Report: ()
Engrossed: ()
Senate Committee Report: ()
Enrolled: ()